Jim Cramer's hopeful on Abbott Labs after court case win
CNBC’s Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that’s been weighed down by ...
Abbott Laboratories’ Legal Victory Strengthens Future Outlook and Supports Buy Rating
Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price ...
Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win
Shares of Abbott Laboratories are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a ...
Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead
A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than ...
Abbott, Mead Johnson Win Defense Verdict Over Preemie Infant Formula
In closing arguments on Wednesday, plaintiff's lawyer Timothy Cronin asked jurors for $6 billion in punitive damages.
Abbott Laboratories: Promising Growth, Yet Fully Valued; A Wait-And-Watch Stock
Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive ...
News Medical on MSN10d
The AI-Powered Lab Assistant with Scientific Awareness
Enhancing healthcare research, Sapio Sciences' solutions unify lab data management, leveraging AI to improve efficiency and ...
Jim Cramer takes a closer looks at the litigation facing Abbott and what it means for the company
Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs.